King Faisal Specialist Hospital, Riyadh – United Arab Emirates
About Dr. Meshari Alzahrani
Dr. Meshari Alzahrani is a Senior Consultant Medical Oncologist specialising in breast cancer. He is recognised as a trusted Medical Oncologist (Breast Cancer) for patients seeking personalised, guideline-concordant breast cancer treatment in Riyadh, Saudi Arabia.
- Internationally fellowship-trained in medical oncology with focus on breast cancer
- 10+ years of experience treating early, locally advanced and metastatic breast cancer
- Expert in HER2-targeted therapy, CDK4/6 inhibitors, PARP inhibitors and immunotherapy
- Active contributor to Saudi national clinical guideline development for breast cancer
- Trusted by international patients for second opinions and complex breast cancer care in Riyadh, Saudi Arabia
Qualifications & Credentials
Medical Degrees
- MBBS — Saudi Medical School
- Residency in Internal Medicine — Saudi Board
Fellowships & Special Training
- Fellowship in Medical Oncology — The Ottawa Hospital, University of Ottawa, Canada
- Advanced training in Breast Oncology and Bone Health in Cancer — Ottawa Hospital Research Institute
Certifications & Accreditations
- Saudi Commission for Health Specialties (SCFHS) Registration
- Member — American Society of Clinical Oncology (ASCO)
- Member — European Society for Medical Oncology (ESMO)
Areas of Expertise
Major Conditions Treated
- Early-Stage Breast Cancer
- Locally Advanced Breast Cancer
- Metastatic (Stage IV) Breast Cancer
- HER2-Positive Breast Cancer
- Triple-Negative Breast Cancer (TNBC)
- Hormone Receptor-Positive Breast Cancer
- Hereditary Breast Cancer (BRCA1/BRCA2)
- Bone Metastases and Skeletal-Related Events
Sub-specialties
- Breast Medical Oncology: Expert in systemic therapy for all breast cancer subtypes — a leading Medical Oncologist (Breast Cancer) specialist in Riyadh, Saudi Arabia for international patients.
- Endocrine & Targeted Therapy: CDK4/6 inhibitors, aromatase inhibitors, anti-HER2 agents and PARP inhibitors tailored to tumour biology.
- Bone-Modifying Agents & Supportive Oncology: Evidence-based use of bisphosphonates and denosumab to reduce skeletal complications — a clinical research interest of Dr. Alzahrani.
Advanced Procedures & Treatments
- Neoadjuvant and Adjuvant Chemotherapy for Breast Cancer
- HER2-Targeted Therapy (Trastuzumab, Pertuzumab, T-DXd)
- CDK4/6 Inhibitors (Palbociclib, Ribociclib, Abemaciclib)
- Immunotherapy for Triple-Negative Breast Cancer
- PARP Inhibitors for BRCA-Mutated Breast Cancer
- Endocrine Therapy for Premenopausal & Postmenopausal Patients
- Bisphosphonate & Denosumab Therapy for Bone Metastases
Professional Experience
Current Affiliation
- King Faisal Specialist Hospital and Research Centre (KFSHRC), Riyadh, Saudi Arabia — Consultant, Breast Cancer Section, Medical Oncology Department, Cancer Centre of Excellence (Present)
Past Affiliations
- The Ottawa Hospital & University of Ottawa, Canada — Medical Oncology Fellow
- Ottawa Hospital Research Institute — Cancer Therapeutics Program (Clinical Research Fellow)
Academic & Research Roles
- Faculty — College of Medicine, Alfaisal University, Riyadh
- Core panellist — 2025 KFSHRC Breast Cancer Consensus (modified Delphi process)
- Participant — KFSHRC Multidisciplinary Breast Tumour Board
Key Achievements
- Co-drafted 35 consensus statements for Saudi national breast cancer management guidelines
- Multiple first- and co-authored publications indexed on PubMed
- Internationally trained with experience managing complex metastatic breast cancer cases
Awards & Recognitions
National & International Awards
- Information not publicly available.
Professional Memberships
- American Society of Clinical Oncology (ASCO)
- European Society for Medical Oncology (ESMO)
- Saudi Oncology Society
Research & Publications
Published Papers (Selected)
- Alaklabi S, Akhtar S, AL-Tweigeri T, Alsayed A, Alzahrani M, Suleman K. "Management of Early and Metastatic Breast Cancer: A Consensus Statement from Oncologists in Saudi Arabia." Oncology and Therapy. 2025. DOI:10.1007/s40487-025-00404-9
- Alzahrani M, Clemons M, Chang L, et al. "Management Strategies for Older Patients with Low-Risk Early-Stage Breast Cancer: A Physician Survey." Current Oncology. 2021;29(1):1-13. DOI:10.3390/curroncol29010001
- McGee S, AlZahrani M, Stober C, et al. "Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation." Journal of Bone Oncology. 2021;27:100351. DOI:10.1016/j.jbo.2021.100351
- AlZahrani M, Clemons M, Vandermeer L, et al. "Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey." Journal of Bone Oncology. 2020;26:100339. DOI:10.1016/j.jbo.2020.100339
Ongoing Research & Clinical Interests
- Optimisation of adjuvant bisphosphonates and denosumab in breast cancer
- De-escalation strategies for low-risk early breast cancer
- Real-world outcomes of CDK4/6 inhibitors in Middle Eastern patients
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (SAR) | Estimated Cost (USD) |
|---|---|---|
| Medical Oncology Consultation | SAR 400 – SAR 1,200 | $110 – $320 |
| Chemotherapy (per cycle, regimen-dependent) | SAR 4,000 – SAR 25,000 | $1,065 – $6,660 |
| HER2-Targeted Therapy (per cycle) | SAR 10,000 – SAR 40,000 | $2,665 – $10,660 |
| CDK4/6 Inhibitor Therapy (per month) | SAR 15,000 – SAR 30,000 | $4,000 – $8,000 |
| Immunotherapy (per cycle) | SAR 18,000 – SAR 45,000 | $4,800 – $12,000 |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Dr. Meshari Alzahrani use in Medical Oncologist (Breast Cancer) treatment?
Dr. Meshari Alzahrani uses the latest evidence-based systemic therapies including HER2-targeted agents (trastuzumab, pertuzumab, T-DXd), CDK4/6 inhibitors, PARP inhibitors, immunotherapy and next-generation endocrine therapy. Biomarker-guided treatment selection is standard. Remote second opinions are available to international patients via Cancer Rounds.
2. What conditions does Dr. Meshari Alzahrani specialize in treating?
Dr. Meshari Alzahrani is a Medical Oncologist (Breast Cancer) specialist treating early-stage, locally advanced and metastatic breast cancer, including HER2-positive, triple-negative, hormone receptor-positive and hereditary (BRCA) breast cancer. Patients from across the Gulf, Africa and beyond seek expert breast cancer treatment in Riyadh, Saudi Arabia.
3. How do I book an appointment with Dr. Meshari Alzahrani?
Appointments with Dr. Meshari Alzahrani can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. Meshari Alzahrani?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Dr. Meshari Alzahrani, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Dr. Meshari Alzahrani offer second opinions for Medical Oncologist (Breast Cancer) cases?
Yes. Second opinion consultations can be arranged via Cancer Rounds for patients who wish to review their diagnosis or treatment plan with an expert Medical Oncologist (Breast Cancer) specialist in Riyadh, Saudi Arabia.
